ELI LILLY AND COMPANY Remaining Share Repurchase Authorization
ELI LILLY AND COMPANY (LLY) had Remaining Share Repurchase Authorization of $12.40 billion as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2025-10-30
- 2025-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $12.40B.
- 2025-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $13.11B.
- 2025-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $13.80B.
- 2024-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $1.98B.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2025-09-30 | $12.40B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $13.11B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $13.80B 10-Q · filed 2025-05-01 |
| 2024-09-30 | $1.98B 10-Q · filed 2024-10-30 |
| 2024-06-30 | $2.50B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.50B 10-Q · filed 2024-04-30 |
| 2023-09-30 | $2.50B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $2.50B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $2.50B 10-Q · filed 2023-04-27 |
| 2022-09-30 | $3.25B 10-Q · filed 2022-11-01 |
| 2022-06-30 | $3.25B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.25B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $4.75B 10-K · filed 2022-02-23 |
| 2021-09-30 | $500.00M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $500.00M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $1.00B 10-Q · filed 2021-04-30 |
| 2020-09-30 | $1.00B 10-Q · filed 2020-10-28 |
| 2020-06-30 | $1.00B 10-Q · filed 2020-07-31 |
| 2020-03-31 | $1.00B 10-Q · filed 2020-05-01 |
| 2019-09-30 | $1.80B 10-Q · filed 2019-10-25 |
| 2019-06-30 | $2.40B 10-Q · filed 2019-08-02 |
| 2019-03-31 | $3.10B 10-Q · filed 2019-05-02 |
| 2018-09-30 | $7.00B 10-Q · filed 2018-11-06 |
| 2018-03-31 | $950.70M 10-Q · filed 2018-04-27 |
| 2017-09-30 | $2.15B 10-Q · filed 2017-10-27 |
| 2017-06-30 | $2.15B 10-Q · filed 2017-07-28 |
| 2017-03-31 | $2.35B 10-Q · filed 2017-05-01 |
| 2016-09-30 | $2.65B 10-Q · filed 2016-10-28 |
| 2016-06-30 | $2.65B 10-Q · filed 2016-07-28 |
| 2016-03-31 | $2.65B 10-Q · filed 2016-04-29 |
| 2015-09-30 | $3.20B 10-Q · filed 2015-10-30 |
| 2015-06-30 | $3.26B 10-Q · filed 2015-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |